Interim report
Page 1
e r$ VIRUPAKSHA To Date: 04.02.2026 The Manager BSE Limited P.J. Towers, Dalal Street Mumbai-400001 Dear Sir/ Madam, Unit: Oxygenta Pharmaceutical Limited (Scrip: 524636) Sub: Outcome of Board Meeting and other matters under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ‘With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04 February, 2026, at 12:00 noon at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH Act) w.e.f, 04.02.2026. (Attached as Annexure -I) The Meeting concluded at 5:50 P.M. This is for the information and records of the Exchange, please. Thanking you. Yours faithfully, For Oxygenta Pharmaceutical Limited Balasubba Reddy Mamilla ‘Whole-time Director (DIN: 01998852) OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An 1SO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad — 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com, Phone 040-23073417, CIN: L24110TG1990PLC012038
Page 2
e Oxygenta VIRUPAKSHA Annexure —I Composition of Internal Complaints Committee (ICC)/POSH Committee S no. | Name of the Member(s) Designation 1. | Mrs. G. Durga Bhavani Presiding Officer 2. | Mr. M. Sreedhar Reddy Internal Member 3. | Mr. P. Nikhil Reddy Internal Member 4. | Mr. K. Mahesh Member 5. | Mr. S. Chandraleka Member 6. | B. Rajitha Member 7. | K. Divya Member 8. | Ms. D. Rajeswari External Member OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED) (An 1SO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company) Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080 Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad — 500 037, Telangana, INDIA. E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com, Phone 040-23073417, CIN: L24110TG1990PLC012038
Page 3
OXYGENTA PHARMACEUTICAL LIMITED CIN : L24110TG1990PLC012038 Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State ‘Corp Office: Leve-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Towaship Hyderabad ‘Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@osygentapharma.com, Phone Number: 040- 23355938 'UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2025 . 7 Previous priodyearfigures havebeen regrouped and reamanged wherever nccsssry tofcilitate comparision, 8 forms confiming their MSME satus. The Companyis carly n th proces of ollcin thee delartions flom supplies to caance ceuracy i Additionally, the Company has yet to mplemnt bill-<-bil. the Compan s o achieving fll and, inits Date: 00272026 [Pace: Hyderabad Products. Henee. ' ot adjustment rocess, which has posedchallengesin prepaing precise agng schedule for ts a5 e IND) AS-108 e ot mad. “The Loss before tax fo the curent quarer s Rs 632.65 Lakhs comparedto Loe Befor tx of R 496,18 Lakbs o th comesponding quartc of he previous yar, DIN 0198852 Rupees in Lakis except for EPS) Quarter Ended ‘Nine months Ended YEAR ENDED s.No Particulars 312205 | sow9n02s | suieoa | swuanes | sunnwes | 3105205 (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) 1| Income from Operations (a)_|Net Sales/Income from Operations (net of excise day) 339309 | 143023 332060 63379 | 598321 10.929.86 |Other Operating Income = (5.62) 48.82 1129 126.00 13091 [Total income from operations (nef) 33909 | Laz4sl 3.369.43 63808 | 6109 1106077 T ST | iwes | srees| ea| senm om0 (b)_[Purchase of stock-in-trade z 5 - & F (©) | Changes in inventories of finished goods, work- in-progress and sto 36.98 (452.80) (576.22)| (486.16)| (351.73) (376.06)| (@) _|Direct Manufacturing Expenses 37691 37934 32095 L1243 773 111609 (9) _[Employee benefit expense 189.04 203.47 183.28 §92.70 47096 684.70 (0 _|Finance Costs 139.08 94.96 38.83 296.88 148.60 36142 () _|Depreciation and amortisation expense 8592 8571 70.60 25636 20153 17816 (®)_|Other expenses 80.79 120 a5 25651 30323 47651 @ _|Prior Period Expense = S [Total expenses 402574 | 206839 3,865.60 843813 | 71642 1246891 3 |Profitfrom operations before other income and exceptional tems (1-2) @269 o78) @s1y] @os0oy| oss) 408.14) 4_|Other income 5 = z B 5 s |Profi from ordinary activities before exceptional items (3+4) @269 (64378) @618 (20%009| (0s22)] 1,408.14) 6 [Exceptiona expensesyincome = (@69) 3 @7.00) 7| Profit/ (Loss) from ordinary actvities before tax (7+ 8) 63265 (6a38) @9618) (09469) (108522)| ,435.19) 8 |Tax (expense)ieredit - - - - - Curreat Tax [ Deferred Tax s3] 5074 (103.36) G0327)| @aoes)] @145, Prior period Income tax adjustment 1596 9 [Net Profit/ (Loss) from ordinary actvies after tax 8430 @93.09) | ase) eus) (1,029.65) 10 [Extraordinary items (net of tax expense ) = - - B " - 11| Net Profit/ (Los) for the period (11+ 12) @430 @oaew) @282)| (,91.02) (@1450) 029.69) 12_|Other Comprehensive Income E = 5 z 1073 13_|Total Comprehensive Income @8430) @93.04) e8| sy (e1450) (1,04038) 14_|Share of Profit(loss) of associates E E = 5 5 B 15 |Minority nterest E E E = = B 16 _|Paid-up equity share capi 3,698.35 3,698.35 3,698.35 3,69835 3,69835 3,698.35 face value Rs. 10/-) 17_|Earnings per share (before extraordinary items) (of Rs.10/- cach ) (not ammualised): (a) Basic (1.32) W) o7 @30)| @) @.36) (b) Diluted (1.32)] (1.33)| (L12)| (4.30) 227)] (@.36) 1%ii_|Earnings per share (after extraordinary items) |(of Rs.10%- each) (not annualised): @) Basic .32) 1.33) .07) (4.30) @27) .86) ) Ditutea 1.32) 1.33) ) (@30) @.27) @39) NoTEs: 1 The above esulis have been evieed by the Audit commite and approved by the Bowr of Direcorsa s mecing held on th Febrary, 2026 at Corprste offcs, Level-1 Plot No B1 and B2, IDA Gandsi Nagar, Balanagar Township Hyderabad 2 The Sttutory Auitorsofthe Company have caried out"Limited Review” o the sbovs unaudited financa esultsandthic Report h b place befoe he Boardat e said Mting o3 reqired ndr Regulaton 33 of EBI| (LODR) Regulaions, 2015 3 e fnancal sl o the company v bécn prepared inaccordance with Indian Aceouting Standards (nd AS) notified under th companies (ndian Accoutin standards) Rulcs, 2015 s amended by he companis (ndian Accouting standards) (mendiment) s, 2016, “The Entir opratons ofthe Company tlate 10 any one segment i of S Total Tumoverfo the curent quarte eporicd Rs 339309 Laks compard fo Rs 33201 for the corresponing quarer ofthe previousyesr, “The Companyis atively working to complete the ideification f s MSME crditrs, hougha e gaps e i thi process To fcilst acrat dentificaon,we Rave requested all supplies 0 submit slfdeclaation ing creditors. Addiessing these outsanding issus remains a prorty, nd. For and on behalf of the Board of Directors B OXYGENTA PHARMACEUTICAL LIMITED- NS ‘Balasubba Reddy Mamilla Whole Time Director ©
Page 4
A.M REDDY & D.R REDDY Chartered Accountants INDIA Independent Auditor’s Review Report on Unaudited Quarterly Financial Results of OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To, The Board of Directors, Oxygenta Pharmaceutical Limited. 1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited (“the Company”) for the quarter ended December 31, 2025 and year to date results for the period April 1st, 2025 to December 31, 2025 (“the Statement™) attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Regulation™) 2. This Statement. which is the responsibility of the company’s Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 “Interim Financial Reporting”, prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to H.O #14/ 186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 |Phone No: 08554-231666 B.0 H.No 3-6-640/1/C, Fourth Floor, Street No 9, Himayat Nagar , Hyderabad 500 029 | Phone No : 040-40077393 Mobile No: 9848032382 Email ID: rkreddy1999#yahoo.com
Page 5
obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion. 4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement. For AMREDDY & D.RREDDY Chartered Accountants Firms Registration No: 009068S Yloozs—| D. Rama Krishna Reddy | Partner Membership No. 209211 UDIN: 262092 11HUDPCV9543 Place: Hyderabad Date: 04/02/2026 H.O #14/ 186, Flat 203, Ananth Sai Residency kamalnagar, Anantapur 515 001 |Phone No: 08554-231666 B.0 H.No 3-6-640/1/C, Fourth Floor, Street No 9, Himayat Nagar , Hyderabad 500 029 | Phone No : 040-40077393 Mobile No: 9848032382 Email ID: rkreddy1999#yahoo.com